Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland.
Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement
Delayed visual evoked response in optic neuritis.
Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis.
Multiple sclerosis disease-modifying therapy and pregnancy.
Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis.
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Health Care Resource Use and Cost Of Multiple Sclerosis in Slovakia: Results from the National Cross-Sectional Study.
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.
LINGO-1, A TRANSMEMBRANE SIGNALING PROTEIN, INHIBITS OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION THROUGH INTERCELLULAR SELF-INTERACTIONS.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Evaluating Working Ability and Quality of Life of Patients with Multiple Sclerosis.
Leptin and other adipokines in EAE and MS
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.
Masitinib mesylate application for conditional approval
Multiple sclerosis: Real-world long-term benefits of disease-modifying MS therapy.
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS.
Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.
Development of oral immunomodulatory agents in the management of multiple sclerosis.
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Partnership and consent in MS treatment choice.
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients